Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate with Clinical Benefit
Results are from a median follow-up of three years SAN DIEGO – An adjuvant treatment regimen that included autogene...
Search/Filter
Loading...
Bispecific Immune Checkpoint Inhibitor Improves Survival in Gastric Cancer Patients Regardless of PD-L1 Status
SAN DIEGO – The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with...
Some Breast Cancer Survivors May Safely De-escalate Mammography Three Years After Surgery
SAN ANTONIO – Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage...
Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients with Low-risk DCIS
MRI and a DCIS gene profile were used to stratify patients for treatment SAN ANTONIO – Patients with low-risk...
Potentially Targetable Fusion RNAs May Be More Common in Metastatic Breast Cancer Than Previously Realized
SAN ANTONIO – Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique...
Patients with HR-positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Study examined pregnancy and cancer outcomes among patients who paused endocrine therapy to conceive SAN ANTONIO – Using fertility...
Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer
Treatment for metastatic disease may last indefinitely, amplifying the need for effective interventions SAN ANTONIO – Among patients with...
Younger Postmenopausal Patients With Early-stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Results are from a five-year follow-up; long-term study is needed SAN ANTONIO – Almost all postmenopausal patients aged 50-69...
Neoadjuvant Chemotherapy May Help Some Breast Cancer Patients Skip Regional Nodal Irradiation
Treatment de-escalation may be an option for patients whose lymph nodes become cancer free after neoadjuvant treatment SAN ANTONIO...
Tucatinib Plus Trastuzumab Emtansine May Benefit Patients With Advanced or Metastatic HER2-positive Breast Cancer
SAN ANTONIO – A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival...